Targeting novel immunosuppressive mechanisms in cancer

LYT-200 (Immuno-oncology)
Anti-Galectin-9 MAb
Solid tumors
H1 2020
LYT-200 (Immuno-oncology)
Anti-Galectin-9 MAb
Solid tumors
H1 2020
A monoclonal antibody-based therapeutic approach aimed at difficult to treat cancer types (pancreatic, liver, cholangio, colorectal)

PureTech is developing two first-in-class, fully human antibodies which are aimed at countering fundamental mechanisms of immunosuppression. PureTech's therapeutic candidates are designed to address cancers that are subotimally treated with currently available standard of care and immunotherapies because the the body's natural defenses are compromised by persistent tumor immune evasion. These antibodies have the potential to be used as single agents in addition to being used in combinatorial approaches (e.g., with checkpoint inhibitors). These programs are based on the research conducted at Professor George Miller's laboratory and are exclusively licensed from NYU School of Medicine. 

LYT-200 is a human IgG4 antibody directed against galectin-9, a global immunosuppressor. Galectin-9 exerts immunosuppression by binding to multiple partners and facilitating a tumor-permissive microenvironment. This antibody has shown excellent physical and functional properties, and exciting proof-of-concept data has been generated in both mouse and human cancer preclinical models.

We are advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD), multiple sclerosis (MS) and various other neuroinflammatory diseases. We are also developing associated clinical monitors and measurement-based care applications. Our lead, patented technology platform is exclusively licensed from the lab of Dr. Adam Gazzaley at the University of California, San Francisco (UCSF), and augmented by proprietary adaptive algorithms developed by our team.

  • Patient Need & Market Potential
    • With a five-year survival rate at less than seven per cent, pancreatic cancer is the third leading cause of cancer death.
    • Globally, approximately 400,000 people are diagnosed with pancreatic cancer each year, with more than 90 per cent diagnosed at an advanced/metastatic stage.
    • Colorectal cancer (CRC) is among the largest cancer burdens in the world today with approximately 700,000 people being diagnosed globally each year. Median survival of patients with unresectable metastatic CRC remains less than three years. Death from CRC is expected to nearly double within the next 20 years. Current immunotherapies are only efficacious in a small proportion of CRC patients (less than 15 per cent) whose tumors demonstrate mismatch repair deficiency. Hence novel, more broadly effective therapeutic strategies to engage the patients’ immune system are needed.
    • Currently approved immunotherapies have been generally unsuccessful in this disease setting due to a highly immunosuppressive environment that wards off the body’s natural defenses.
    • PureTech’s galectin-9/gamma delta T-cell program aims to address this underlying issue and the great unmet need in malignancies, particularly those with dismal prognoses that derive little benefit from current standards of care
  • Our Approach to Solving the Problem
    • Preclinical models validating PureTech’s therapeutic concept show survival extensions in gold-standard animal models of pancreatic cancer that are superior to those previously observed in literature using approved treatments.
    • PureTech’s approach is differentiated from traditional checkpoint inhibitors in immuno-oncology, yet it has potential synergies with existing immunotherapies and current standards-of-care. It may also have broader applicability in the immuno-oncology space, with research underway expanding this initial work in pancreatic cancer and other solid tumors, including CRC, cholangiocarcinoma, gastric and breast cancers.
  • Intellectual Property
    • PureTech has broad intellectual property coverage for this antibody-based immunotherapy technology, including exclusive rights to fifteen (15) patent applications in four (4) families of patent filings that are exclusively licensed from or co-owned with New York University which cover antibodies that target immunosuppressive T-cells and methods of use for the treatment of solid tumors.
  • Milestones Achieved
    • In April 2017, PureTech publicly disclosed these programs (originally called “Nybo”) concurrent with a publication in Nature Medicine.
    • PureTech has developed fully human monoclonal antibodies to target newly discovered immunosuppressive mechanisms in pancreatic cancer and other solid tumors. Proof-of-concept data has been generated in both mouse and human cancer preclinical models.
  • Collaborations
    • PureTech’s gamma delta T-cells/galectin-9 technology is exclusively licensed from the NYU School of Medicine and is based on the pioneering work of Dr. George Miller, Director of S. Arthur Localio Laboratories and Director of the Cancer Immunology Program at NYU School of Medicine. Part of the body of data supporting this approach was published in Nature Medicine and builds upon Dr. Miller’s work previously published in Cell.
  • Expected Milestones and Timing
    • PureTech expects to file an IND for its lead candidate, LYT-200, in the first half of 2020.

An IND filing is anticipated for LYT-200 in the first half of 2020.